Levamisol Arena (Levamisole Hydrochloride)

Levamisole is used to treat parasitic worm infections affecting the gastrointestinal tract.

• Ascariasis: eliminates Ascaris lumbricoides worms and reduces associated gastrointestinal symptoms.
• Hookworm infection: eradicates Ancylostoma duodenale and Necator americanus and alleviates anemia.
• Trichuriasis: removes Trichuris trichiura and improves bowel function.

• Levamisole acts as an agonist at nicotinic acetylcholine receptors on nematode muscle cells, causing sustained depolarization, paralysis, and expulsion of the parasite. In addition, it modulates the host immune response by enhancing T‑cell activity and cytokine production, which contributes to its therapeutic effect against helminths.

Levamisole may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: transient stomach upset after dosing.
• Vomiting: occasional emesis, usually self‑limiting.
• Abdominal pain: mild cramping or discomfort.
• Dizziness: transient light‑headedness.
• Skin rash: mild erythema or pruritus.
• Mild leukopenia: slight reduction in white‑blood‑cell count.

Serious or Rare Side Effects

• Agranulocytosis: severe drop in neutrophils, requiring immediate medical attention.
• Stevens‑Johnson syndrome: rare severe skin reaction with blistering.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Severe neutropenia: marked decrease in neutrophils, increasing infection risk.
• Anaphylaxis: rare systemic allergic reaction.

Before prescribing Levamisol Arena, clinicians should consider several safety aspects.

• Pregnancy: safety not established; avoid unless benefits outweigh risks.
• Breastfeeding: unknown excretion; consider alternative therapy.
• Renal impairment: use with caution and monitor renal function.
• Hematologic monitoring: obtain baseline complete blood count and repeat as needed.
• Concomitant immunosuppressants: assess infection risk before co‑administration.
• Store at room temperature: keep in the original container, protect from moisture and light.

Levamisole can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid)

• Immunosuppressants: may increase risk of severe infection.
• Cytotoxic chemotherapy: additive bone‑marrow suppression.
• Live vaccines: reduced efficacy and possible infection.

Moderate Interactions (Monitor Closely)

• Anticoagulants: potential enhancement of bleeding.
• CYP450 inhibitors/inducers: may alter levamisole plasma levels.
• Other anthelmintics: possible additive toxicity, monitor for adverse signs.